AU2001234164A1 - Process for producing avermectin derivative - Google Patents

Process for producing avermectin derivative

Info

Publication number
AU2001234164A1
AU2001234164A1 AU2001234164A AU3416401A AU2001234164A1 AU 2001234164 A1 AU2001234164 A1 AU 2001234164A1 AU 2001234164 A AU2001234164 A AU 2001234164A AU 3416401 A AU3416401 A AU 3416401A AU 2001234164 A1 AU2001234164 A1 AU 2001234164A1
Authority
AU
Australia
Prior art keywords
dihydroavermectin
medicine
avermectin
production
avermectin derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001234164A
Inventor
Hirofumi Endo
Shinichi Hashimoto
Haruo Ikeda
Yutaka Kanda
Satoshi Omura
Hiroyuki Yamaguchi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kitasato Institute
KH Neochem Co Ltd
Original Assignee
Kitasato Institute
Kyowa Hakko Kogyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kitasato Institute, Kyowa Hakko Kogyo Co Ltd filed Critical Kitasato Institute
Publication of AU2001234164A1 publication Critical patent/AU2001234164A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C327/00—Thiocarboxylic acids
    • C07C327/20—Esters of monothiocarboxylic acids
    • C07C327/30—Esters of monothiocarboxylic acids having sulfur atoms of esterified thiocarboxyl groups bound to carbon atoms of hydrocarbon radicals substituted by nitrogen atoms, not being part of nitro or nitroso groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

According to the present invention, 22,23-dihydroavermectin B1a, which is useful as a medicine, a veterinary drug, and a pesticide, can be directly fermented and produced. This can obviate the need for the complicated and difficult conventional processes for purifying avermectin B1a at an industrial level and for chemically modifying avermectin B1a and can significantly decrease cost and time required in the industrial production of 22,34-dihydroavermectin B1a. The production of the formulation containing only 22,23-dihydroavermectin B1a, which is highly effective as a medicine, is also realized.
AU2001234164A 2000-02-24 2001-02-23 Process for producing avermectin derivative Abandoned AU2001234164A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2000047405 2000-02-24
JP2000-47405 2000-02-24
PCT/JP2001/001381 WO2001062939A1 (en) 2000-02-24 2001-02-23 Process for producing avermectin derivative

Publications (1)

Publication Number Publication Date
AU2001234164A1 true AU2001234164A1 (en) 2001-09-03

Family

ID=18569657

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001234164A Abandoned AU2001234164A1 (en) 2000-02-24 2001-02-23 Process for producing avermectin derivative

Country Status (7)

Country Link
US (1) US20040101936A1 (en)
EP (1) EP1270728B1 (en)
AT (1) ATE360086T1 (en)
AU (1) AU2001234164A1 (en)
CA (1) CA2402398A1 (en)
DE (1) DE60127948T2 (en)
WO (1) WO2001062939A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002006345A2 (en) * 2000-07-18 2002-01-24 Curagen Corporation G-protein coupled receptor proteins (gpcr) and nucleic acids encoding same
US7081213B2 (en) 2002-05-14 2006-07-25 Clariant Finance (Bvi) Limited Stabilizer mixtures for the protection of polymer substrates
CN102144163A (en) * 2008-04-10 2011-08-03 麻省理工学院 Methods for identification and use of agents targeting cancer stem cells
US10106778B2 (en) 2012-11-08 2018-10-23 Whitehead Institute For Biomedical Research Selective targeting of cancer stem cells
US10398672B2 (en) 2014-04-29 2019-09-03 Whitehead Institute For Biomedical Research Methods and compositions for targeting cancer stem cells
CN113930407A (en) * 2021-05-28 2022-01-14 湖北中农华威生物工程有限公司 Hydrolase and application thereof in biocatalytic synthesis of 4 '-methylamino-5' -hydroxy-avermectin

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ233116A (en) * 1989-03-31 1994-09-27 Merck & Co Inc Cloning genes from steptomyces avermitilis for avermectin biosynthesis
JP3002347B2 (en) * 1992-12-24 2000-01-24 社団法人北里研究所 Direct fermentation method of 5-oxo-avermectin derivative and microorganism producing the same
US6066721A (en) * 1995-07-06 2000-05-23 Stanford University Method to produce novel polyketides
GB9814622D0 (en) * 1998-07-06 1998-09-02 Biotica Tech Ltd Polyketides,their preparation,and materials for use therein
US6197591B1 (en) * 1998-09-14 2001-03-06 Pfizer Inc. Streptomyces avermitilis regulatory genes for increased avermectin production
WO2000044717A2 (en) * 1999-01-27 2000-08-03 Kosan Biosciences, Inc. Synthesis of oligoketides
JP2000245457A (en) * 1999-02-24 2000-09-12 Kitasato Inst:The Avermectin aglycon synthetase

Also Published As

Publication number Publication date
CA2402398A1 (en) 2001-08-30
EP1270728B1 (en) 2007-04-18
DE60127948T2 (en) 2008-01-17
WO2001062939A1 (en) 2001-08-30
DE60127948D1 (en) 2007-05-31
EP1270728A4 (en) 2004-11-24
EP1270728A1 (en) 2003-01-02
ATE360086T1 (en) 2007-05-15
US20040101936A1 (en) 2004-05-27

Similar Documents

Publication Publication Date Title
AU6701890A (en) Process for the production of biologically active protein
AU6194694A (en) Nor-bile acid derivatives, processes for their preparation and the use of these compounds as medicaments
WO2003000699A8 (en) Substituted 1-oxa-2,8-diaza-spiro[4,5]dec-2-ene derivatives as medicaments for the treatment of pain
TW239144B (en)
WO2002096457A3 (en) Stable liquid formulations of antibodies
WO2001089571A3 (en) Method of increased bioavailability of nutrients and pharmaceutical preparations with tetrahydropiperine and its analogues and derivatives
EP0404283A3 (en) 11-beta-aryl-4-estrene, method for its production and its use as a medicine
AU7581394A (en) Galanthamine derivatives, a process for their preparation and their use as medicaments
AU2001234164A1 (en) Process for producing avermectin derivative
AU7696396A (en) Diaminopyrimidines, pharmaceutical compositions containing them and their use as antibacterial
IL124523A (en) Methoxyacrylic acid derivatives, a process for their production and use thereof in controlling insects, acarinas and phytopathogenic microorganisms
WO2002055491A3 (en) 1,2-DISUBSTITUTED CYCLIC INHIBITORS OF MATRIX METALLORPROTEASES AND TNF-$g(a)
HUT67040A (en) Heterocyclic-substituted phenyl-cyclohexane-carboxylic acid derivatives, process for producing them and pharmaceutical compositions containing them
DK1123937T3 (en) Substance GM-95, process for its preparation and use thereof
WO2003059262A3 (en) Method and composition for treating and preventing hiv infection and aids
AU695190B2 (en) Substance FA-70D, process for producing the same, and uses thereof
WO2002055516A3 (en) 1,1-DISUBSTITUTED CYCLIC INHIBITORS OF MATRIX METALLOPROTEASE AND TNF-$g(a)
AU7022694A (en) Ester compound, active agent for controlling noxious insect pests containing the same as active ingredient, alcohol compound for production of the ester compound and process for producing the alcohol compound
EP1162191A3 (en) (1S,6R)- And/or (1R,6S)-2,2,6-trimethylcyclohexyl methyl ketone, process for producing the same, and perfume composition containing the same
HUT50633A (en) Process for producing pharmaceutical compositions comprising 1,4-dihydropyridine derivatives
YU67203A (en) Caloporoside-derivatives, methods for the production thereof and their use
BR9900620A (en) Lactone terpenoid compounds and their production process.
WO2003029495A3 (en) Coniosulphides and their derivatives, method for their production and use as medicaments
WO2003031381A3 (en) Synthesis of (z)-3,5,4'-trimethoxystilbene, and use thereof
WO2003013498A3 (en) Nitrate ester-cyclodextrin complexes for treating diseases, particularly coronary diseases